Clinical trials: AIDS-Related Kaposi Sarcoma
AIDS-Related Kaposi Sarcoma, Recurrent Kaposi Sarcoma
Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma
This phase I/II trial studies the side effects and best dose of lenalidomide and to see how well it works in treating patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (KS).
- Trial name
- NCT01057121
- Testing
- Lenalidomide
- Where
- 13 sites in United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Kaposi's Sarcoma AIDS Related, Kaposi's Sarcoma Classical
AIDS and Cancer Specimen Bank (ACSB)
The purpose of this study is to obtain clinical specimens from pathologists and physicians involved in the diagnosis and care of patients with AIDS and non-AIDS associated malignancies.
- Conditions
- Kaposi's Sarcoma AIDS Related, Kaposi's Sarcoma Classical, Non-Hodgkin's Lymphoma, HEMATOPOIETIC SYSTEM
- Trial name
- NCT00587912
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
AIDS-Related Kaposi Sarcoma, Skin Kaposi Sarcoma
Nirogacestat in Patients With Kaposi Sarcoma
This phase II trial studies how well nirogacestat works in treating patients with skin Kaposi sarcoma (KS). Several anti-cancer drugs work well in treating KS, but there is no treatment that cures KS.
- Trial name
- NCT07539454
- Testing
- Biospecimen Collection, Chest Radiography, Computed Tomography
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- AIDS Malignancy Consortium
Lymphoma
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
- Trial name
- NCT00598169
- Testing
- rituximab, bortezomib, carboplatin
- Where
- 17 sites in United States
- Volunteers
- 23 people
- Sponsor
- AIDS Malignancy Consortium
Ovarian Cancer, AIDS-related Kaposi Sarcoma
Doxil/Caelyx BE Study
The aim of this study is to demonstrate the bioequivalence of DOXIL/CAELYX, 40 mg/m2 (IV infusion over 90 minutes) between two manufacturing facilities.
- Conditions
- Ovarian Cancer, AIDS-related Kaposi Sarcoma, Multiple Myeloma, Metastatic Breast Cancer
- Trial name
- NCT05567601
- Testing
- DOXIL/CAELYX
- Where
- 14 sites in India
- Volunteers
- 36 people
- Sponsor
- Baxter Healthcare Corporation
Sarcoma, Kaposi, HIV Infections
A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma
To evaluate tolerance, toxicity, and preliminary evidence of antitumor efficacy of intralesionally administered tumor necrosis factor (TNF) and to define a maximum tolerated dose (MTD) for single intralesional injections.
- Trial name
- NCT00002262
- Testing
- Tumor Necrosis Factor
- Where
- United States
- Sponsor
- University of California, San Francisco
AIDS-related Kaposi's Sarcoma
A Study of Selumetinib in Patients With Kaposi's Sarcoma
Cancer is a leading cause of death in individuals living with human immunodeficiency virus (HIV), and Kaposi's sarcoma (KS) remains the commonest HIV-associated cancer.
- Trial name
- SCART (NCT01752569)
- Testing
- Selumetinib
- Where
- 6 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Classical Kaposi's Sarcoma
Treatment of Classical Non-HIV-Related Kaposi's Sarcoma With the Antiviral Drug Indinavir
Recent studies have described a reduced incidence or the regression of Kaposi's sarcoma (KS) in HIV-infected patients treated with the highly active anti-retroviral therapy (HAART) that contains at least one inhibitor of the HIV…
- Trial name
- NCT00362310
- Testing
- indinavir
- Where
- 9 sites in Italy
- Volunteers
- 28 people
- Sponsor
- Istituto Superiore di Sanità